Family Blood Pressure Program - HyperGEN

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Donna K. Arnett, PhD, Professor, Chair, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00005267
First received: May 25, 2000
Last updated: June 18, 2012
Last verified: June 2012
  Purpose

To map and identify the major genetic determinants of hypertension and to study possible interactions between genetic and non-genetic factors in defined populations. HyperGEN initially consisted of a nine grant network, which in turn is part of an NHLBI initiative, the Family Blood Pressure Program (FBPP) consisting of four networks.


Condition
Cardiovascular Diseases
Heart Diseases
Hypertension

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Biospecimen Retention:   Samples With DNA

Tissue suitable for DNA extraction


Enrollment: 3604
Study Start Date: September 1995
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

(A) sample of hypertensive sibships with at least two members diagnosed with hypertension before the age of 60 (probands); (B) random sample of age-matched persons from the same base populations, from which normotensive controls could be drawn; (C) unmedicated, normotensive adult offspring of one of the hypertensive siblings.

Criteria

Inclusion criteria for probands: Onset of hypertension by age 60 years and the presence of at least one additional hypertensive sibling who was willing to participate. Hypertension was defined according to systolic BP ≥140 or diastolic BP ≥90 in at least two different evaluations, or treatment for hypertension. Volunteers with type 1 diabetes or renal failure were excluded.

Inclusion criteria for subsequent recruits: Criteria as indicated in Study Population Description (i.e., criteria based on familial relationships, hypertension and antihypertensive medication status).

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005267

Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Principal Investigator: Donna Arnett University of Alabama at Birmingham
Principal Investigator: John Eckfeldt University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: R.Curtis Ellison Boston University
Principal Investigator: Steven Hunt University of Utah
Principal Investigator: Jean-Marc Lalouel University of Utah
Principal Investigator: Cora Lewis University of Alabama at Birmingham
Principal Investigator: Kari North University of North Carolina
Principal Investigator: James Pankow University of Minnesota - Clinical and Translational Science Institute
Principal Investigator: Dabeeru Rao Washington University School of Medicine
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Donna K. Arnett, PhD, Professor, Chair, Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00005267     History of Changes
Other Study ID Numbers: 1151, 5R01HL055673-15
Study First Received: May 25, 2000
Last Updated: June 18, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Hypertension
Vascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013